<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242460</url>
  </required_header>
  <id_info>
    <org_study_id>PORYOU</org_study_id>
    <nct_id>NCT03242460</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)</brief_title>
  <acronym>PORYOU</acronym>
  <official_title>The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-labeled, Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kosin University Gospel Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Korea, VMP is most commonly used as frontline treatment in patients with newly diagnosed&#xD;
      MM who were ineligible for high-dose therapy. Recently National Insurance began to reimburse&#xD;
      the second-line LD when the bortezomib-containing treatment failed to salvage the patients.&#xD;
      Patients who have relapsed MM after exposure to the above agents and have progressive disease&#xD;
      have a short life expectancy. Third-line therapy is needed for retrieving the patients&#xD;
      hereafter. And substantial proportion of patients will attain an advanced age. To examine if&#xD;
      time to disease progression is maintained and tolerability is improved with lower&#xD;
      dexamethasone dose, the dose of dexamethasone is reduced when at least a minimal response is&#xD;
      achieved after 3 months of treatment with the initial dose. Three months later (6 months&#xD;
      after the initial treatment), the response remains in stable disease, 2nd dose reduction&#xD;
      (dexamethasone 10mg or prednisone 50mg) will be carried out.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 12, 2015</start_date>
  <completion_date type="Actual">May 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>the transplant-ineligible patients with Relapsed and/or refractorY multiple myeloma (MM) who had lenalidomide+dexamethasone (LD) following frontline bortezomib combined chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Kaplan-Meier method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>2 years follow up</time_frame>
    <description>International Myeloma Working Group,( IMWG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluations assessed using Common Terminology Criteria for Adverse Events v4.0</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Common Terminology Criteria for Adverse Events v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Relapsed and/or refractorY Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide, Dexamethasone, Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide 4 MG</intervention_name>
    <description>Pomalidomide 4mg Days 1-21</description>
    <arm_group_label>Pomalidomide, Dexamethasone, Cyclophosphamide</arm_group_label>
    <other_name>pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 20mg</intervention_name>
    <description>Dexamethasone 20mg Days 1, 8, 15, 22</description>
    <arm_group_label>Pomalidomide, Dexamethasone, Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 400mg</intervention_name>
    <description>Cyclophosphamide 400mg Days 1, 8, 15</description>
    <arm_group_label>Pomalidomide, Dexamethasone, Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have evaluable multiple myeloma with at least one of the following&#xD;
             (within 21 days of starting treatment)&#xD;
&#xD;
               -  Serum M-protein ≥ 0.5g/dL, or&#xD;
&#xD;
               -  In subjects without detectable serum M-protein, Urine M-protein ≥ 200mg/24 hour,&#xD;
                  or serum free light chai (sFLC) &gt; 100mg/L (involved light chain) and an abnormal&#xD;
                  kappa/Lambda ratio&#xD;
&#xD;
          -  Patients were ineligible for autologous stem cell transplantation&#xD;
&#xD;
          -  Must be relapse refractory to initial therapy with bortezomib, melphalan and prednison&#xD;
             and then lenalidomide plus dexamethasone.&#xD;
&#xD;
          -  Refractoriness is defined as disease progression on treatment or progression within 6&#xD;
             months after the last dose of a given therapy. Relapse is defined according to the&#xD;
             criteria of IMWG&#xD;
&#xD;
          -  Males and females ≥ 18 years of age or &gt; country's legal age for adult consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2&#xD;
&#xD;
          -  Patients must meet the following clinical laboratory criteria with 21 days of starting&#xD;
             treatment:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 (≥&#xD;
                  30,000/mm3 if myeloma involvement in the bone marrow is &gt;50%)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). Alanine&#xD;
                  aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30mL/min or creatinine &lt; 3mg/dL.&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local and institutional&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are lactating or pregnant&#xD;
&#xD;
          -  Multiple Myeloma of IgM subtype&#xD;
&#xD;
          -  Glucocorticoid therapy (prednisolone &gt; 30mg/day or equivalent) within 14 days prior to&#xD;
             informed consent obtained&#xD;
&#xD;
          -  POEMS syndrome, plasma cell leukemia or circulating plasma cells ≥ 2 x 109/L,&#xD;
             Waldenstrom's Macroglobulinaemia, or Patients with known amyloidosis&#xD;
&#xD;
          -  Peripheral neuropathy grade &gt; 2&#xD;
&#xD;
          -  Chemotherapy with approved or investigation anticancer therapeutics within 21 days&#xD;
             prior to starting pomalidomide treatment&#xD;
&#xD;
          -  Focal radiation therapy within 7 days prior to start of pomalidomide. Radiation&#xD;
             therapy to an extended field involving a significant volume of bone marrow within 21&#xD;
             days prior to start of pomalidomide&#xD;
&#xD;
          -  Immunotherapy (excluding steroids) 21 days prior to start of pomalidomide&#xD;
&#xD;
          -  Major surgery (excluding kyphoplasty) within 28 days prior to start of pomalidomide&#xD;
&#xD;
          -  Active congestive heart failure (New York Heart Association [NYHA] Class III or IV),&#xD;
             symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional&#xD;
             intervention. Myocardial infarction within 4 months prior to informed consent obtained&#xD;
&#xD;
          -  Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients&#xD;
             with hepatitis B surface antigen or core antibody receiving and responding to&#xD;
             antiviral therapy directed at hepatitis B: these patients are allowed)&#xD;
&#xD;
          -  Second malignancy within the past 3 years except:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Breast carcinoma in situ with full surgical resection&#xD;
&#xD;
          -  Patients with steroid or lenalidomide hypersensitivity&#xD;
&#xD;
          -  Patients with pleural effusions requiring thoracentesis or ascites requiring&#xD;
             paracentesis within 14 days prior to starting pomalidomide treatment&#xD;
&#xD;
          -  Any clinically significant medical disease or psychiatric condition that, in the&#xD;
             investigator's opinion, may interfere with protocol adherence or a patient's ability&#xD;
             to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic university of korea, Seoul ST. Mary's Hospital.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kosin University Gospel Hospital</investigator_affiliation>
    <investigator_full_name>Ho Sup Lee</investigator_full_name>
    <investigator_title>MD, PhD. associate professor, Division of hematology-Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>KMMWP</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

